CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*

The FDA placed a clinical hold on the islatravir development program in late 2021, but new data reported at HIV Glasgow 2022 identify an optimized dose that permits resumed clinical development of this investigational reverse-transcriptase translocation inhibitor. Here are my thoughts on what we learned.

Babafemi Taiwo, MBBS Released: November 17, 2022

As the use of 2-drug antiretroviral therapy regimens for HIV treatment continues to increase, so does the importance of ensuring that our patients have adequate HBV immunity. This highlights the significance of an IDWeek 2022 presentation evaluating the recently approved HepB-CpG vaccine in people with HIV.

Joseph J. Eron, Jr., MD Released: November 22, 2022

In Central and Eastern Europe, the Russian invasion of Ukraine is affecting HIV care, with an impact being seen on PrEP implementation in Ukraine and HIV treatment for refugees in Poland.

Milosz Parczewski, MD, PhD Released: November 22, 2022

As this new option starts to become available in Spain, I take a look at how new data presented at HIV Glasgow 2022 will affect my clinical practice.

José R. Arribas, MD Released: November 21, 2022

In expanded multivariable analyses from ATLAS, ATLAS-2M, and FLAIR of people with HIV receiving long-acting cabotegravir plus rilpivirine, factors most predictive of confirmed virologic failure were preexisting rilpivirine resistance-associated mutations and HIV-1 subtype A6/A1.

Darrell H. S. Tan, MD, FRCPC, PhD Released: November 22, 2022

Do the results with long-acting ART in real-world settings match what we saw in clinical trials? Here are my thoughts on the latest data from the fall 2022 HIV conferences.

Don Smith, MD Released: November 22, 2022

A modeling analysis of islatravir doses predicted that at 0.25 mg daily, lymphocyte changes would be similar to other ART regimens and effective concentrations would be reached. In the real-world US OPERA Cohort, long-acting cabotegravir plus rilpivirine was highly effective.

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

At IDWeek 2022, investigators reported new findings from a long-term analysis of the randomized START trial comparing immediate vs delayed ART initiation. The results continue to reinforce the benefits of early vs later ART start and also support strategies in China that have successfully decreased time to ART initiation among newly diagnosed individuals.

Yan Zhao, MD Released: November 22, 2022

To me, the most important analysis presented at the fall conferences for HIV healthcare professionals in Sub-Saharan Africa was a plenary presentation addressing progress and challenges related to identifying and treating cryptococcal meningitis in PWH .

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

回顾专家教员对 IDWeek 和 HIV Glasgow 2022 的关键 HIV 研究的总结，包括预防策略、长效疗法、日常口服疗法、研究性药物以及 HIV 和 COVID-19 的研究结果。

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 16, 2022

Reveja os resumos dos principais estudos de VIH dos membros do corpo docente especialistas do IDWeek e VIH Glasgow 2022, incluindo resultados de estudos de estratégias de prevenção, terapias de ação prolongada, terapias orais diárias, agentes de investigação e VIH e COVID-19.

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 16, 2022

Ознакомьтесь с обзорами ключевых исследований ВИЧ по итогам IDWeek и HIV Glasgow 2022, составленными экспертным профессорским составом, включая результаты исследований стратегий профилактики, длительного лечения, ежедневного перорального лечения, экспериментальных препаратов и взаимодействия ВИЧ и COVID-19.

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 16, 2022

Consulte los resúmenes de estudios clave sobre el VIH presentados en la Semana de las Enfermedades Infecciosas (IDWeek 2022) y el Congreso Internacional sobre Terapia Farmacológica del VIH (HIV Glasgow 2022) que ha redactado un panel de expertos y que incluyen los resultados de estudios relativos a las estrategias de prevención, los tratamientos de acción prolongada, los tratamientos diarios de administración oral, los fármacos en fase de investigación, el VIH y la COVID-19.

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 16, 2022

Hear from expert faculty as they present their insights on some of the most clinically relevant new data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Hear from expert faculty as they present their insights on some of the most clinically relevant new data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.

Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Listen to expert insights from Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, on some of the most clinically relevant new HIV data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.

Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 5, 2022

Review expert faculty members’ summaries of key HIV studies from IDWeek and HIV Glasgow 2022, including results from studies of prevention strategies, long-acting therapies, daily oral therapies, investigational agents, and HIV and COVID-19.

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022